Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-128-1
CAS number: 68411-46-1
The repeated dose toxicity data shows both adaptive and adverse effects
on liver, so it is proven that at least some of the components of the
UVCB substance are taken up and transported into the liver after
ingestion. Representative components are shown in the figure below.
Depending on the location and possible sterical hindrance, oxidative
metabolism at the secondary amine is possible. Based on textbook
knowledge of xenobiotic metabolism, both ring-hydroxylation and
side-chain hydroxylation are possible. Coupling in phase II metabolism
would result in more soluble metabolites that could be eliminated both
via bile and kidney. Actual rate of uptake and elimination will depend
on the grade and type of alkylation as this affects solubility and type
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again